Patents by Inventor James J. Stec, II

James J. Stec, II has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Novel compositions and methods for identification, assessment, prevention, and therapy of ovarian cancer
    Publication number: 20090136961
    Abstract: The present invention is directed to the identification of markers that can be used to determine whether ovarian cancer is sensitive or resistant to a therapeutic agent. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with sensitivity or resistance to a therapeutic agent. Thus, by examining the expression of the individual markers of a marker set, also referred to as the expression profile of the marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of the ovarian cancer.
    Type: Application
    Filed: November 18, 2008
    Publication date: May 28, 2009
    Applicants: Millennium Pharmaceuticals, Inc., Board of Regents, Mayo Foundation for Medical Education and Research
    Inventors: Andrew I. Damokosh, Natalia Lartchouk, James J. Stec, II, Edwin A. Clark, Karen Lu, Lynn Hartmann, Robert C. Bast, JR., Gordon B. Mills
  • Compositions and methods for the identification, assessment, prevention and therapy of ovarian cancer
    Patent number: 7470509
    Abstract: The present invention is directed to the identification of markers that can be used to determine whether ovarian cancer is sensitive or resistant to a therapeutic agent. In particular, the present invention is directed to the use of certain combinations of markers, wherein the expression of the markers correlates with sensitivity or resistance to a therapeutic agent. Thus, by examining the expression of the individual markers of a marker set, also referred to as the expression profile of the marker set, it is possible to determine whether a therapeutic agent, or combination of agents, will be most likely to reduce the growth rate of the ovarian cancer.
    Type: Grant
    Filed: February 7, 2003
    Date of Patent: December 30, 2008
    Assignee: Millennium Pharmaceuticals, Inc.
    Inventors: Andrew I. Damokosh, Natalia Iartchouk, James J. Stec, II, Edwin A. Clark, Karen Lu, Lynn Hartmann, Robert C. Bast, Jr., Gordon B. Mills